Dr. John R Douglas Peterson, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr Ste 3300, Washington, MO 63090 Phone: 636-239-7344 |
Dr. Carl F Blatt Jr., M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr, Washington, MO 63090 Phone: 636-239-7344 Fax: 636-239-9436 |
Sheetal Sharma, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 901 Patients First Dr, Suite 2000, Washington, MO 63090 Phone: 636-239-7344 Fax: 636-239-9436 |
Leslie E Tucker, M.D. Internal Medicine - Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 901 Patients First Dr, Washington, MO 63090 Phone: 636-239-7344 Fax: 636-239-9436 |
News Archive
Celleration, Inc., a privately-held medical device company focused on developing and commercializing therapeutic ultrasound healing technologies, announced the first patient enrollment in IN-BALANCE VLU (Inflammation, Bacteria, & Angiogenesis effects in Launching Venous Leg Ulcer healing: A Clinical Evaluation).
Fibrocell Science, Inc. announced today that the Company has completed a private placement with certain accredited investors, pursuant to which the Company sold to the purchasers an aggregate of 41,409,458 shares of Company common stock at a purchase price of $0.55 per share.
A new study shows that quitting smoking after a heart attack has immediate benefits, including less chest pain, better quality of daily life and improved mental health. Many of these improvements became apparent as little as one month after quitting and are more pronounced after one year, according to the research at Washington University School of Medicine in St. Louis.
Researchers at Washington University School of Medicine in St. Louis have received a $9 million grant to investigate blood-clotting disorders. From heart attacks and strokes to uncontrolled bleeding, clotting disorders cause more deaths each year in the United States than all types of cancer combined.
The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
› Verified 7 days ago